Table 1.
Clinical and demographic characteristics of the study population overall, and when stratified by presence or absence of adjuvant therapy receipt.
| Characteristic | Overalla (n=253) | No Adjuvant Treatment (n = 145) | Any Adjuvant Treatment (n = 100) | P-value |
|---|---|---|---|---|
|
| ||||
| Mean age at diagnosis in years (SD) | 59.8 (12.5) | 58.6 (12.8) | 61.1 (11.7) | 0.09 |
|
| ||||
| Mean tumor size in cm (SD) b | 4.3 (2.5) | 4.0 (2.6) | 4.7 (2.4) | 0.01 |
|
| ||||
| Histology, n (%) | <0.001 | |||
| Endometrioid | 210 (83%) | 138 (95%) | 66 (66%) | |
| Mixed | 31 (12%) | 3 (2%) | 26 (26%) | |
| Non-endometrioid | 12 (5%) | 4 (3%) | 8 (8%) | |
|
| ||||
| Histologic grade, n (%) c | <0.001 | |||
| Grade 1 | 37 (15%) | 35 (24%) | 2 (2.0%) | |
| Grade 2 | 151 (60%) | 97 (68%) | 50 (50%) | |
| Grade 3 | 63 (25%) | 11 (8%) | 48 (48%) | |
|
| ||||
| Deep (≥50%) myometrial invasion, n (%) d | 53 (21%) | 13 (9%) | 38 (38%) | <0.001 |
|
| ||||
| Lymphatic/vascular space invasion, n (%) e | 79 (32%) | 19 (14%) | 58 (58%) | <0.001 |
|
| ||||
| CTNNB1 mutation present, n (%) | 45 (18%) | 30 (21%) | 14 (14%) | 0.18 |
a
Adjuvant treatment data missing for n=8 patients
b
Tumor size data missing for n=13 patients
c
Histologic grade data missing for n=2 patients
d
Depth of myometrial invasion data missing for n=3 patients
e
Lymphatic/vascular space invasion data missing for n=6 patients
SD, standard deviation.